French Pharma Stock News

Bharti Space Limited’s purchase of 88.7 million Eutelsat Communications (ENXTPA:ETL) shares on 16 December is a big governance moment, tightening its grip on the satellite operator’s future direction. See our latest analysis for Eutelsat Communications. That move comes after a bruising stretch for investors, with a 30 day share price return of minus 47.1 percent and a five year total shareholder return of minus 72.1 percent. As a result, any sign of strategic conviction now looks like an...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...

Edenred (ENXTPA:EDEN) is quietly tightening its grip on Europe’s electric trucking transition, teaming up with Daimler Truck to power the new TruckCharge Network and expand access via its UTA Edenred and Spirii platforms. See our latest analysis for Edenred. Against that backdrop, Edenred’s 30 day share price return of 1.95% offers only a modest pause in what has been a much tougher spell. The year to date share price return is down 39.71 percent and the five year total shareholder return has...

Schneider Electric (ENXTPA:SU) has been quietly grinding higher over the past month, adding about 6% even after a softer past week. That mix of short term noise and steady gains makes the current setup interesting. See our latest analysis for Schneider Electric. That recent 6.4% 1 month share price return sits against a slightly negative year to date move, while a modest 1 year total shareholder return of 0.7% caps a far stronger 3 year total shareholder return above 90%. This suggests...

Sanofi (ENXTPA:SAN) shares have quietly bounced about 2% over the past week, even though they are still down for the year, drawing attention from investors looking for more resilient pharma exposure. See our latest analysis for Sanofi. That recent 7 day share price return of 2.21 percent only slightly offsets a year to date share price decline of 12.66 percent. This suggests sentiment is stabilising rather than surging, despite steady earnings growth and pipeline progress. If Sanofi has you...

Kering (ENXTPA:KER) has quietly climbed this year, and with the share price hovering around €303 after a recent pullback, investors are starting to reassess whether the luxury group’s recovery has more room to run. See our latest analysis for Kering. The recent pullback sits against a strong backdrop, with a roughly 28 percent year to date share price return. This suggests sentiment toward Kering’s turnaround is improving even as the three and five year total shareholder returns remain deeply...

Nexans S.A. ( EPA:NEX ), might not be a large cap stock, but it received a lot of attention from a substantial price...

Key Insights Given the large stake in the stock by institutions, Alten's stock price might be vulnerable to their...

Veolia Environnement SA ( EPA:VIE ) saw its share price hover around a small range of €28.40 to €29.97 over the last...

If you are wondering whether Sanofi is quietly turning into a bargain while everyone is focused on flashier names, this deep dive will help you assess whether the current price reflects its long term potential. Despite a solid 5 year gain of 28.1%, the stock is down 12.7% year to date and 4.6% over the last month, suggesting that sentiment has cooled even as the long term story remains intact. Recently, markets have been reacting to Sanofi's strategic shifts in its pharmaceutical pipeline...

If you are wondering whether LVMH Moët Hennessy Louis Vuitton Société Européenne is still a quality luxury name at a fair price, you are not alone. That is exactly what we are going to unpack here. The share price has been relatively steady but slightly positive, up around 1.2% over the last week and 3.6% over the past month, while sitting roughly flat year to date and modestly higher over 1 year. This hints at cautious optimism rather than a runaway rally. Recent headlines have focused on...

Wondering if Publicis Groupe is quietly turning into a value opportunity, or if the market has already priced in the upside? The stock has edged up about 1.5% over the last week and 5.5% over the past month, even though it is still down roughly 13.9% year to date and 10.2% over the last year after a very strong 3 and 5 year run. Recent headlines have focused on Publicis tightening its focus on high margin data and tech led services and securing new global client mandates, reinforcing its...

In July 2025, Laura Burdese took over as CEO of Bulgari, succeeding long-time leader Jean-Christophe Babin, who remains chairman and head of the Bulgari Hotel business unit. This leadership reshuffle at one of LVMH’s key jewelry and hospitality brands could subtly reshape how the group balances heritage with expansion. We’ll now explore how Burdese’s appointment at Bulgari might influence LVMH’s broader investment narrative, especially around brand diversification and luxury hospitality. The...

If you are wondering whether Atos at around €46 is a turnaround bargain or a value trap, you are not the only one. That is exactly what this breakdown is going to tackle. The stock has swung hard lately, down 15.9% over the last week but still up 6.0% over 30 days, with an eye catching 85.8% gain year to date and a 121.2% rise over the past year after a brutal multi year slide. Those moves come after years of restructuring and strategic shifts that have investors rethinking the long term...

Sanofi halted development of tolebrutinib in primary progressive multiple sclerosis after the drug missed its Phase 3 primary endpoint. The company signed a licensing deal worth up to $1.04 billion with ADEL for an investigational Alzheimer’s antibody. Sanofi expanded its collaboration with Dren Bio to advance next generation B cell targeted therapies for autoimmune diseases. Regulatory progress includes approvals for new rare disease medicines in China and EMA orphan designation for an...

Thales (ENXTPA:HO) just rolled out its AI Security Fabric, a platform aimed at shielding Agentic AI and LLM apps from threats like prompt injection and data leakage, and the stock is starting to reflect that shift. See our latest analysis for Thales. That launch lands after a strong run, with the latest share price at €231.2 and a year to date share price return of 68.02 percent. The five year total shareholder return of 241.04 percent shows longer term momentum has been firmly building...

There are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...

Gaztransport & Technigaz (ENXTPA:GTT) has caught investors attention after naming François Michel as its next CEO, effective January 2026. The move restores split governance and sharpens focus on technology driven growth. See our latest analysis for Gaztransport & Technigaz. The appointment of François Michel comes after a choppy stretch, with a 1 month share price return of minus 13.0% even as the year to date share price return is still up 15.2% and the 1 year total shareholder return of...

On 5 December 2025, Dynamatic Technologies Limited announced an expanded agreement with Dassault Aviation to manufacture and assemble the complete rear fuselage (Section 5) of the Falcon 6X, building on its earlier work industrialising the rear fuel tank already in commercial production. This deeper manufacturing role not only strengthens Dassault Aviation’s supply chain for the Falcon 6X, but also broadens its industrial footprint in India under the Make in India policy, potentially...

SPIE (ENXTPA:SPIE) just deepened its relationship with Tesla through a multi year European framework agreement for battery energy storage projects, a strategic move that plugs SPIE directly into the grid scale transition story. See our latest analysis for SPIE. Those moves sit against a strong backdrop, with the share price up sharply this year on the back of the Tesla framework, energy transition acquisitions and an upcoming anti dilutive buyback, signalling building momentum and improving...

If you are wondering whether Engie is still good value after such a strong run, or if you are turning up late to the party, this breakdown will help you decide whether the current price still makes sense. Engie’s share price has barely moved over the last week (up 0.4%) and month (down 0.3%). However, those quiet short term moves sit on top of a 40.0% gain year to date and a 58.6% rise over the past year, with returns of 110.9% over 3 years and 158.8% over 5 years. Part of this strength...

Sanofi recently reported that its PERSEUS Phase 3 trial found the multiple sclerosis drug tolebrutinib failed to delay disability progression in primary progressive MS, leading the company to stop seeking approval for this indication while the FDA review for non‑relapsing secondary progressive MS is pushed beyond the previously expected December 2025 decision date. At the same time, Sanofi has expanded its presence in rare blood disorders in China with approvals for Qfitlia in hemophilia and...

If you are wondering whether Pluxee is a beaten down opportunity or a value trap at its current price, this is a good place to unpack what the market might be missing. The stock has been choppy lately, up 1.8% over the last week but still down 4.5% over 30 days and roughly 29% lower year to date. This naturally raises questions about whether sentiment has swung too far. Recent coverage has focused on Pluxee's standalone positioning in employee benefits and engagement solutions following its...

Eurofins Scientific (ENXTPA:ERF) has quietly outperformed this year, with the stock up roughly 20% year to date, despite a more mixed picture over the past month and quarter. See our latest analysis for Eurofins Scientific. That 19.5% year to date share price return, alongside a 23% one year total shareholder return, suggests sentiment has been steadily improving as investors reassess Eurofins Scientific's growth prospects and risk profile around its current €58.26 share price. If Eurofins's...